Attenuated TLR4/MAPK signaling in monocytes from patients with CRMO results in impaired IL-10 expression

Clinical Immunology

Volumn 145, Issue 1, 2012, Pages 69-76

  Hofmann, Sigrun R ^a   Morbach, Henner ^b   Schwarz, Tobias ^b   Rösen Wolff, Angela ^a   Girschick, Hermann J ^c   Hedrich, Christian M ^a,d  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Chromatin; CNO; CRMO; Histone; IL 10; Sp 1

Indexed keywords

HISTONE H3; INTERLEUKIN 10; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SERINE; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR SP1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BONE DISEASE; CELL ISOLATION; CHRONIC OSTEOMYELITIS; CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EPIGENETICS; HUMAN; HUMAN TISSUE; MONOCYTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION;

CHROMATIN; GENE EXPRESSION; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MONOCYTES; OSTEOMYELITIS; PHOSPHORYLATION; PRIMARY CELL CULTURE; PROMOTER REGIONS, GENETIC; PROTEIN KINASES; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865459912     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2012.07.012     Document Type: Article

References (38)

1. Bjorksten B., Gustavson K.H., Eriksson B., Lindholm A., Nordstrom S. Chronic recurrent multifocal osteomyelitis and pustulosis palmoplantaris. J. Pediatr. 1978, 93:227-231.
2. Giedion A., Holthusen W., Masel L.F., Vischer D. Subacute and chronic "symmetrical" osteomyelitis. Ann. Radiol. (Paris) 1972, 15:329-342.
3. Girschick H.J., Raab P., Surbaum S., Trusen A., Kirschner S., Schneider P., Papadopoulos T., Muller-Hermelink H.K., Lipsky P.E. Chronic non-bacterial osteomyelitis in children. Ann. Rheum. Dis. 2005, 64:279-285.
4. Hofmann S.R., Schwarz T., Moller J.C., Morbach H., Schnabel A., Rosen-Wolff A., Girschick H.J., Hedrich C.M. Chronic non-bacterial osteomyelitis is associated with impaired Sp1 signaling, reduced IL10 promoter phosphorylation, and reduced myeloid IL-10 expression. Clin. Immunol. 2011, 141:317-327.
5. Huber A.M., Lam P.Y., Duffy C.M., Yeung R.S., Ditchfield M., Laxer D., Cole W.G., Kerr G.H., Allen R.C., Laxer R.M. Chronic recurrent multifocal osteomyelitis: clinical outcomes after more than five years of follow-up. J. Pediatr. 2002, 141:198-203.
6. Jurik A.G. Chronic recurrent multifocal osteomyelitis. Semin. Musculoskelet. Radiol. 2004, 8:243-253.
7. Morbach H., Dick A., Beck C., Stenzel M., Muller-Hermelink H.K., Raab P., Girschick H.J. Association of chronic non-bacterial osteomyelitis with Crohn's disease but not with CARD15 gene variants. Rheumatol. Int. 2010, 30:617-621.
8. Schultz C., Holterhus P.M., Seidel A., Jonas S., Barthel M., Kruse K., Bucsky P. Chronic recurrent multifocal osteomyelitis in children. Pediatr. Infect. Dis. J. 1999, 18:1008-1013.
9. Girschick H.J., Zimmer C., Klaus G., Darge K., Dick A., Morbach H. Chronic recurrent multifocal osteomyelitis: what is it and how should it be treated?. Nat. Clin. Pract. Rheumatol. 2007, 3:733-738.
10. Hedrich C.M., Bream J.H. Cell type-specific regulation of IL-10 expression in inflammation and disease. Immunol. Res. 2010, 47:185-206.
11. Hofmann S.R., Rosen-Wolff A., Tsokos G.C., Hedrich C.M. Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury. Clin. Immunol. 2012, 143:116-127.
12. Tone M., Powell M.J., Tone Y., Thompson S.A., Waldmann H. IL-10 gene expression is controlled by the transcription factors Sp1 and Sp3. J. Immunol. 2000, 165:286-291.
13. Lucas M., Zhang X., Prasanna V., Mosser D.M. ERK activation following macrophage FcgammaR ligation leads to chromatin modifications at the IL-10 locus. J. Immunol. 2005, 175:469-477.
14. Zhang X., Edwards J.P., Mosser D.M. Dynamic and transient remodeling of the macrophage IL-10 promoter during transcription. J. Immunol. 2006, 177:1282-1288.
15. Hedrich C.M., Tsokos G.C. Epigenetic mechanisms in systemic lupus erythematosus and other autoimmune diseases. Trends Mol. Med. 2011, 17:714-724.
16. Meda F., Folci M., Baccarelli A., Selmi C. The epigenetics of autoimmunity. Cell. Mol. Immunol. 2011, 8:226-236.
17. Wilson C.B., Rowell E., Sekimata M. Epigenetic control of T-helper-cell differentiation. Nat. Rev. Immunol. 2009, 9:91-105.
18. Vega M.I., Huerta-Yepaz S., Garban H., Jazirehi A., Emmanouilides C., Bonavida B. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene 2004, 23:3530-3540.
19. Ma W., Lim W., Gee K., Aucoin S., Nandan D., Kozlowski M., az-Mitoma F., Kumar A. The p38 mitogen-activated kinase pathway regulates the human interleukin-10 promoter via the activation of Sp1 transcription factor in lipopolysaccharide-stimulated human macrophages. J. Biol. Chem. 2001, 276:13664-13674.
20. Brightbill H.D., Plevy S.E., Modlin R.L., Smale S.T. A prominent role for Sp1 during lipopolysaccharide-mediated induction of the IL-10 promoter in macrophages. J. Immunol. 2000, 164:1940-1951.
21. Chanteux H., Guisset A.C., Pilette C., Sibille Y. LPS induces IL-10 production by human alveolar macrophages via MAPKinases- and Sp1-dependent mechanisms. Respir. Res. 2007, 8:71.
22. Guha M., Mackman N. LPS induction of gene expression in human monocytes. Cell. Signal. 2001, 13:85-94.
23. van der B.T., Nijenhuis S., van R.E., Verhoef J., van Asbeck B.S. Lipopolysaccharide-induced tumor necrosis factor alpha production by human monocytes involves the raf-1/MEK1-MEK2/ERK1-ERK2 pathway. Infect. Immun. 1999, 67:3824-3829.
24. Aksentijevich I., Masters S.L., Ferguson P.J., Dancey P., Frenkel J., van Royen-Kerkhoff A., Laxer R., Tedgard U., Cowen E.W., Pham T.H., Booty M., Estes J.D., Sandler N.G., Plass N., Stone D.L., Turner M.L., Hill S., Butman J.A., Schneider R., Babyn P., El-Shanti H.I., Pope E., Barron K., Bing X., Laurence A., Lee C.C., Chapelle D., Clarke G.I., Ohson K., Nicholson M., Gadina M., Yang B., Korman B.D., Gregersen P.K., van Hagen P.M., Hak A.E., Huizing M., Rahman P., Douek D.C., Remmers E.F., Kastner D.L., Goldbach-Mansky R. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 2009, 360:2426-2437.
25. Lindor N.M., Arsenault T.M., Solomon H., Seidman C.E., McEvoy M.T. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin. Proc. 1997, 72:611-615.
26. Wise C.A., Gillum J.D., Seidman C.E., Lindor N.M., Veile R., Bashiardes S., Lovett M. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum. Mol. Genet. 2002, 11:961-969.
27. Beck C., Girschick H.J., Morbach H., Schwarz T., Yimam T., Frenkel J., van Gijn M.E. Mutation screening of the IL-1 receptor antagonist gene in chronic non-bacterial osteomyelitis of childhood and adolescence. Clin. Exp. Rheumatol. 2011, 29:1040-1043.
28. Shoham N.G., Centola M., Mansfield E., Hull K.M., Wood G., Wise C.A., Kastner D.L. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:13501-13506.
29. Yu J.W., Fernandes-Alnemri T., Datta P., Wu J., Juliana C., Solorzano L., McCormick M., Zhang Z., Alnemri E.S. Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. Mol. Cell 2007, 28:214-227.
30. Hofmann S.R., Roesen-Wolff A., Hahn G., Hedrich C.M. Update: cytokine dysregulation in chronic nonbacterial osteomyelitis (CNO). Int. J. Rheumatol. 2012, 2012:310206.
31. Janssens S., Beyaert R. Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol. Cell 2003, 11:293-302.
32. Girschick H.J., Huppertz H.I., Harmsen D., Krauspe R., Muller-Hermelink H.K., Papadopoulos T. Chronic recurrent multifocal osteomyelitis in children: diagnostic value of histopathology and microbial testing. Hum. Pathol. 1999, 30:59-65.
33. Park-Min K.H., Ji J.D., Antoniv T., Reid A.C., Silver R.B., Humphrey M.B., Nakamura M., Ivashkiv L.B. IL-10 suppresses calcium-mediated costimulation of receptor activator NF-kappa B signaling during human osteoclast differentiation by inhibiting TREM-2 expression. J. Immunol. 2009, 183:2444-2455.
34. Eleftheriou D., Gerschman T., Sebire N., Woo P., Pilkington C.A., Brogan P.A. Biologic therapy in refractory chronic non-bacterial osteomyelitis of childhood. Rheumatology (Oxford) 2010, 49:1505-1512.
35. Marangoni R.G., Halpern A.S. Chronic recurrent multifocal osteomyelitis primarily affecting the spine treated with anti-TNF therapy. Spine (Phila Pa 1976) 2010, 35:E253-E256.
36. Stichweh D.S., Punaro M., Pascual V. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. Pediatr. Dermatol. 2005, 22:262-265.
37. Schnellbacher C., Ciocca G., Menendez R., Aksentijevich I., Goldbach-Mansky R., Duarte A.M., Rivas-Chacon R. Deficiency of interleukin-1 receptor antagonist responsive to anakinra. Pediatr. Dermatol. 2012, [Electronic publication ahead of print].
38. ter Haar N.M., van R.A., van Gijn M.E., Frenkel J. DIRA: life-threatening but treatable inherited inflammatory disease. Ned. Tijdschr. Geneeskd. 2010, 154:A1601.